Initial Serologic Testing for Celiac Disease in First-Degree Relatives
Order tissue transglutaminase IgA (TG2-IgA) and total serum IgA levels as the initial blood work for celiac disease screening in a patient whose parent has celiac disease. This two-test combination is the most accurate and cost-effective approach for detecting celiac disease in at-risk populations 1.
Recommended Testing Algorithm
Primary Testing Panel
- TG2-IgA (tissue transglutaminase IgA antibody): This is the single most efficient serological test for celiac disease diagnosis 1, 2
- Total serum IgA level: Essential to identify IgA deficiency, which occurs in approximately 2-3% of celiac patients and would cause false-negative TG2-IgA results 1
Why This Specific Combination
The 2019 AGA guidelines explicitly state that serology is crucial for celiac disease detection, with TG2-IgA and IgA testing being the cornerstone 1. First-degree relatives of celiac patients are at significantly higher risk than the general population, making them appropriate candidates for screening even without symptoms 3, 4.
The patient must be consuming gluten-containing foods at the time of testing - gluten avoidance prior to testing reduces sensitivity of both serology and biopsy 1. If the patient has already started avoiding gluten, they should resume eating at least three slices of wheat bread daily for 1-3 months before testing 1.
If IgA Deficiency is Detected
When total IgA is low or undetectable, the TG2-IgA result becomes unreliable. In this scenario, order 1, 5:
- IgG-based testing: Either TG2-IgG, IgG deamidated gliadin peptide (DGP-IgG), or IgG endomysial antibodies
- Note: IgG testing for TG2 is not specific in the absence of IgA deficiency and should not be ordered routinely 1
Common Pitfalls to Avoid
Do not order deamidated gliadin peptide antibodies (DGP-IgG/IgA) for initial testing - these are no longer recommended as first-line tests 5, 2. Antigliadin tests have been superseded by more accurate antibody testing.
Do not order endomysial antibodies (EMA-IgA) as initial screening - while highly specific, EMA testing is more expensive and technically demanding. It is reserved for confirmation in specific situations, such as when TG2-IgA is ≥10× upper limit of normal and a no-biopsy diagnosis is being considered 1, 5.
Next Steps Based on Results
If TG2-IgA is Positive
- ≥10× upper limit of normal: Refer to gastroenterology; may qualify for no-biopsy diagnosis in children if confirmed with positive EMA-IgA in a second sample 1, 5
- <10× upper limit of normal: Refer to gastroenterology for endoscopy with duodenal biopsies (at least 4 from distal duodenum, plus 1 from bulb) 1, 6
If TG2-IgA is Negative
The patient is unlikely to have celiac disease, though this does not completely exclude it. Consider HLA-DQ2/DQ8 testing only if clinical suspicion remains very high despite negative serology, as the absence of these genes has high negative predictive value 1.
Important Context for First-Degree Relatives
First-degree relatives have approximately 10-15% lifetime risk of developing celiac disease 4. They may present with atypical or no symptoms, making serologic screening particularly valuable in this population 3, 7. The testing approach is identical whether the patient is symptomatic or asymptomatic, though clinical context influences interpretation and follow-up decisions.